1. Market Research
  2. > All Companies
  3. > Medullary Thyroid Cancer - Pipeline Review, H1 2016

Medullary Thyroid Cancer - Pipeline Review, H1 2016

  • March 2016
  • -
  • Global Markets Direct
  • -
  • 97 pages

Medullary Thyroid Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Medullary Thyroid Cancer - Pipeline Review, H1 2016’, provides an overview of the Medullary Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
- The report reviews pipeline therapeutics for Medullary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Medullary Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Medullary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Medullary Thyroid Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Medullary Thyroid Cancer - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Medullary Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Medullary Thyroid Cancer - Overview 8
Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis 9
Medullary Thyroid Cancer - Therapeutics under Development by Companies 10
Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11
Medullary Thyroid Cancer - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Medullary Thyroid Cancer - Products under Development by Companies 14
Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes 15
Medullary Thyroid Cancer - Companies Involved in Therapeutics Development 16
Advenchen Laboratories, LLC 16
Ariad Pharmaceuticals, Inc. 17
Boehringer Ingelheim GmbH 18
Celgene Corporation 19
Hutchison MediPharma Limited 20
Immunomedics, Inc. 21
Nerviano Medical Sciences S.r.l. 22
Novartis AG 23
Medullary Thyroid Cancer - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AL-3818 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
CLM-29 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
CLM-94 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
everolimus - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
GI-6207 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
HMPL-012 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
nintedanib - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
NMS-616 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
pasireotide - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
ponatinib hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Pz-1 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
TF-2 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Medullary Thyroid Cancer - Recent Pipeline Updates 64
Medullary Thyroid Cancer - Dormant Projects 92
Medullary Thyroid Cancer - Discontinued Products 93
Medullary Thyroid Cancer - Product Development Milestones 94
Featured News and Press Releases 94
Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013 94
Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 94
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 97

List of Tables
Number of Products under Development for Medullary Thyroid Cancer, H1 2016 8
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Medullary Thyroid Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 16
Medullary Thyroid Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 17
Medullary Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 18
Medullary Thyroid Cancer - Pipeline by Celgene Corporation, H1 2016 19
Medullary Thyroid Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016 20
Medullary Thyroid Cancer - Pipeline by Immunomedics, Inc., H1 2016 21
Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2016 22
Medullary Thyroid Cancer - Pipeline by Novartis AG, H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Medullary Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2016 64
Medullary Thyroid Cancer - Dormant Projects, H1 2016 92
Medullary Thyroid Cancer - Discontinued Products, H1 2016 93

List of Figures
Number of Products under Development for Medullary Thyroid Cancer, H1 2016 8
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Top 10 Targets, H1 2016 25
Number of Products by Stage and Top 10 Targets, H1 2016 25
Number of Products by Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cancer Cachexia Global Clinical Trials Review, H1, 2016

Cancer Cachexia Global Clinical Trials Review, H1, 2016

  • $ 2 500
  • Company report
  • February 2016
  • by Global Data

Cancer Cachexia Global Clinical Trials Review, H1, 2016 Summary GlobalData's clinical trial report, “Cancer Cachexia Global Clinical Trials Review, H1, 2016" provides an overview of Cancer Cachexia clinical ...

Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2016

Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2016

  • $ 2 500
  • Company report
  • February 2016
  • by Global Data

Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2016 Summary GlobalData's clinical trial report, “Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2016" provides an overview of ...

Barretts Esophagus Global Clinical Trials Review, H1, 2016

Barretts Esophagus Global Clinical Trials Review, H1, 2016

  • $ 2 500
  • Company report
  • April 2016
  • by Global Data

Barretts Esophagus Global Clinical Trials Review, H1, 2016 Summary GlobalData's clinical trial report, “Barretts Esophagus Global Clinical Trials Review, H1, 2016" provides an overview of Barretts Esophagus ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.